



Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 55298

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

8 Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China

Yin ZZ *et al.* Adjuvant nab-paclitaxel plus gemcitabine

Zhu-Zeng Yin, Zhi-Ming Zhao, Wen-Bo Tang, Nan Jiang, Ke-Di Zhang, Yu-Yao Song, Yang Wang, Cheng-Gang Li, Yuan-Xing Gao, Rong Liu

Abstract

BACKGROUND

Nab-paclitaxel plus gemcitabine (AG) has resulted in higher tumor response and survival rates for metastatic or advanced pancreatic ductal adenocarcinoma (PDAC) compared with gemcitabine (GEM) alone.

AIM

To examine the feasibility and safety of AG adjuvant chemotherapy of resectable PDAC.

METHODS

Match Overview

1	Internet 26 words crawled on 23-May-2020 www.wjgnet.com	1%
2	Internet 20 words crawled on 15-Dec-2017 www.bjorl.org	1%
3	Crossref 19 words Tatsuma Sakaguchi, Sohei Satoi, Tomohisa Yamamoto, S o Yamaki, Mitsugu Sekimoto. "The past, present, and fut	1%
4	Internet 19 words crawled on 21-Apr-2020 www.researchsquare.com	1%
5	Crossref 16 words Uesaka, Katsuhiko, Narikazu Boku, Akira Fukutomi, Yukiyasu Okamura, Masaru Konishi, Ippei Matsumoto, Yuji Ka	1%
6	Internet 16 words crawled on 13-Apr-2018 www.oncotarget.com	1%
7	Crossref 15 words Gary Middleton, Daniel H Palmer, William Greenhalf, Paul a Ghaneh et al. "Vandetanib plus gemcitabine versus pla	1%
8	Crossref 14 words Zhuzeng Yin, Rong Liu. "Adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine in resected pancreatic ductal adenocarcinoma: A single center experience in China"	1%



Adjuvant Nab-paclitaxel plus Gemcitabine versus Gemcit



ALL

IMAGES

VIDEOS

21,400 Results

Any time ▾

Adjuvant nab-paclitaxel plus gemcitabine versus ...

<https://ascopubs.org/doi/abs/10.1200/JGO.2019.5.suppl.85>

85. Background: Adjuvant chemotherapy with gemcitabine (GEM) is standard care for resected pancreatic ductal adenocarcinoma (PDAC). Nab-paclitaxel plus gemcitabine (AG) vs gemcitabine (GEM) have shown better survival and tumor response with in advanced or metastatic PDAC.

Author: Zhuzeng Yin, Rong Liu Publish Year: 2019

Adjuvant nab-paclitaxel plus gemcitabine versus ...

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e15740

e15740. Background: Adjuvant chemotherapy with gemcitabine (GEM) is standard care for resected pancreatic ductal adenocarcinoma (PDAC). Nab-paclitaxel plus gemcitabine (AG) vs gemcitabine (GEM) have shown better survival and tumor response with in advanced or metastatic PDAC.

Author: Zhuzeng Yin, Rong Liu Publish Year: 2019

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as ...

<https://www.mayo.edu/research/clinical-trials/cls-20144018> ▾

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (the "Apact" Study) ... Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1). ... nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian ...

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as ...

<https://clinicaltrials.gov/ct2/show/NCT01964430> ▾

ABI-007-PANC-003 is a Phase 3, international, multicenter, randomized, open-label, controlled study that will compare the efficacy of nab-paclitaxel in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 cycles in patients with surgically resected pancreatic adenocarcinoma.

APACT Trial - The ASCO Post

<https://www.ascopost.com/issues/july-10-2019/apact-trial> ▾

Adjuvant Nab-paclitaxel PLUS Gemcitabine. The phase III APACT trial evaluated adjuvant treatment with nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with resected pancreatic

Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone



ALL

IMAGES

VIDEOS

22,500 Results

Any time ▾

[Adjuvant nab-paclitaxel plus gemcitabine versus ...](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e15740)

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e15740

e15740 Background: **Adjuvant** chemotherapy with **gemcitabine** (GEM) is standard care for **resected pancreatic ductal adenocarcinoma** (PDAC). **Nab-paclitaxel plus gemcitabine** (AG) vs **gemcitabine** (GEM) have shown better survival and tumor response with in advanced or metastatic PDAC. We aimed to determine the efficacy and safety of AG compared with GEM for **resected ...**

Author: Zhuzeng Yin, Rong Liu **Publish Year:** 2019

[Adjuvant nab-paclitaxel plus gemcitabine versus ...](https://ascopubs.org/doi/abs/10.1200/JGO.2019.5.suppl.85)

<https://ascopubs.org/doi/abs/10.1200/JGO.2019.5.suppl.85>

85 Background: **Adjuvant** chemotherapy with **gemcitabine** (GEM) is standard care for **resected pancreatic ductal adenocarcinoma** (PDAC). **Nab-paclitaxel plus gemcitabine** (AG) vs **gemcitabine** (GEM) have shown better survival and tumor response with in advanced or metastatic PDAC. We aimed to determine the efficacy and safety of AG compared with GEM for **resected ...**

Author: Zhuzeng Yin, Rong Liu **Publish Year:** 2019

[Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as ...](https://www.mayo.edu/research/clinical-trials/cls-20144018)

<https://www.mayo.edu/research/clinical-trials/cls-20144018>

The phase III MPACT trial (N = 861) demonstrated superior overall survival (OS) with first-line **nab-paclitaxel plus gemcitabine** versus **gemcitabine alone** (median, 8.7 months vs 6.6 months; hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.62-0.83; P 0.001) in patients with metastatic **pancreatic cancer**. The efficacy benefit of the ...

[Comparative Effectiveness of Gemcitabine plus Nab ...](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520876)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520876>

Apr 05, 2019 · Braiteh F., Patel M.B., Parisi M., Ni Q., Park S., Faria C. Comparative effectiveness and resource utilization of **nab-paclitaxel plus gemcitabine vs. FOLFIRINOX** or **gemcitabine** for the first-line treatment of metastatic **pancreatic adenocarcinoma** in a US community setting.



22,700 Results

Any time ▾

[Adjuvant nab-paclitaxel plus gemcitabine versus ...](#)

<https://ascopubs.org/doi/abs/10.1200/JGO.2019.5.suppl.85>

85 Background: **Adjuvant** chemotherapy with **gemcitabine** (GEM) is standard care **for resected pancreatic ductal adenocarcinoma** (PDAC). **Nab-paclitaxel plus gemcitabine** (AG) **vs gemcitabine** (GEM) have shown better survival and tumor response with in advanced or metastatic PDAC. We aimed to determine the efficacy and safety of AG compared with GEM **for resected** PDAC. Methods: We ...

Author: Zhuzeng Yin, Rong Liu **Publish Year:** 2019

[Adjuvant nab-paclitaxel plus gemcitabine versus ...](#)

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e15740

e15740 Background: **Adjuvant** chemotherapy with **gemcitabine** (GEM) is standard care **for resected pancreatic ductal adenocarcinoma** (PDAC). **Nab-paclitaxel plus gemcitabine** (AG) **vs gemcitabine** (GEM) have shown better survival and tumor response with in advanced or metastatic PDAC. We aimed to determine the efficacy and safety of AG compared with GEM **for resected** PDAC. Methods: We ...

Author: Zhuzeng Yin, Rong Liu **Publish Year:** 2019

[Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as ...](#)

<https://www.mayo.edu/research/clinical-trials/cls-20144018>

The phase III MPACT trial (N = 861) demonstrated superior overall survival (OS) with first-line **nab-paclitaxel plus gemcitabine** versus **gemcitabine alone** (median, 8.7 months **vs** 6.6 months; hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.62-0.83; P 0.001) in patients with metastatic **pancreatic** cancer. The efficacy benefit of the ...

[Are We Sure that Adjuvant Chemotherapy is the Best ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912693>

Nov 08, 2019 · 3. **Adjuvant** Treatment—The Data. Up to a 30% 5-year survival rate can be achieved if **adjuvant** chemotherapy is delivered after surgical resection []. Since CONKO-001 demonstrated the efficacy of **gemcitabine** (GEM) as a postoperative **adjuvant** treatment in 2007 [13,53] with a 5-year survival rate of 20.7%, it has become the standard of care. The 5-year survival rate was estimated in ...